News
RTGN
4.000
NaN%
--
Based on the provided financial report articles, I generated the title for the article: **"Sanovas, Inc. (RTGN) Financial Report for Fiscal Year 2025 and 2024"** Please note that the title may not be exact, as the provided text appears to be a financial report with various sections and data, and the title may not be explicitly stated.
Press release · 04/16 07:11
RetinalGenix Reports on its Science and Mission in Light of New AI-Driven Retinal Mapping Study
Barchart · 01/14 05:01
RetinalGenix announces key mangement changes
Seeking Alpha · 12/09/2025 07:22
RetinalGenix Technologies Contracts with Seer Bio to Explore Early Detection of Neurodegenerative, Systemic, and Retinal Diseases
Barchart · 10/16/2025 04:01
RetinalGenix Technologies Advances Home and Remote Monitoring Patent Portfolio, Positioning for the Future of Ocular and Systemic Disease Care
Barchart · 09/25/2025 05:15
Weekly Report: what happened at RTGN last week (0908-0912)?
Weekly Report · 09/15/2025 10:43
Weekly Report: what happened at RTGN last week (0901-0905)?
Weekly Report · 09/08/2025 10:45
Weekly Report: what happened at RTGN last week (0825-0829)?
Weekly Report · 09/01/2025 10:41
Weekly Report: what happened at RTGN last week (0818-0822)?
Weekly Report · 08/25/2025 10:50
Weekly Report: what happened at RTGN last week (0811-0815)?
Weekly Report · 08/18/2025 10:44
More
Webull provides a variety of real-time RTGN stock news. You can receive the latest news about RETINALGENIX TECHNOLOGIES INC through multiple platforms. This information may help you make smarter investment decisions.
About RTGN
RetinalGenix Technologies Inc. is an ophthalmic research and development company seeking to revolutionize early disease detection and improve patient outcomes across multiple disease areas. The Company's proprietary High-Resolution Retinal Imaging and DNA/RNA/GPS Pharmaco-Genetic Mapping technologies are designed to help prevent blindness by detecting initial physiological changes that could indicate future ocular and systemic diseases affecting neurodegenerative, cardiovascular, vascular and metabolic systems, as well as diabetic conditions, Alzheimer’s disease and Parkinson’s disease. Its RetinalCam is an in-home/remote location patient-activated monitoring and imaging device offering real-time communication and alerting system for physicians available 24/7. It is also engaged in the development of its product candidates: RTG-2023 and RTG-2024. RTG-2023 for the treatment of dry age-related macular degeneration (dry AMD). RTG-2024 for the treatment of Alzheimer’s syndrome dementia.